Wearable Visual Cues in Parkinson's Disease

Sponsor
Habilita, Ospedale di Sarnico (Other)
Overall Status
Completed
CT.gov ID
NCT05478187
Collaborator
(none)
52
1
2
26
2

Study Details

Study Description

Brief Summary

One of the most disabling features of Parkinson's disease (PD) is represented by the gait disturbances. Some systematic reviews and meta-analysis have showed that conventional physical therapy might improve gait as well as balance, mobility and functional reach in subjects affected by PD. In addition, several studies and reviews support the effectiveness of external sensory cueing, by means of rhythmic auditory or visual cues, in improving kinematic parameters of gait (gait cadence, stride length, velocity, and postural stability) and the functional performance in people with PD, at least in the short-term. Specifically, cueing refers to the use of temporal or spatial stimuli to regulate movement and facilitate functional performance for individual with motor dysfunction. Basal ganglia act as internal triggers of neuronal activity in the supplementary motor area for well-learned, automatic movement sequences, such as locomotion. This mechanism is damaged in individuals with PD, and external cues may act as an attention resource to compensate the deficient internal rhythm due to basal ganglia dysfunction. Subjects can be coached in concentrating their attention on gait by specific self-prompting instructions or by cues stimulation or a combination of these. Movements generated by the presence of external sensory cues are prompted to use alternative (cortical, parieto-premotor) neuronal pathways which have not been damaged by neuronal degeneration of PD, bypassing the automatic basal ganglia network. Recent studies have provided preliminary evidence that visual cueing based on laser shoes and laser canes may reduce freezing, an established risk for falls, with improvement that can be observed for a variable period of time after rehabilitative intervention. In light of the evidence of effectiveness of cueing, developing wearable devices able to generate cues that match with step and that are effective, easy to use and low cost, would be challenging but very appropriate. The aim of this study was to investigate the non-inferiority of a wearable device producing visual cues (Q-Walk system, QUICKLYPRO s.r.l., Bergamo, Italy) in order to improve gait and balance PD patients, compared to a conventional training (stripes on the floor).

Condition or Disease Intervention/Treatment Phase
  • Device: QWalk Study Group
  • Other: Traditional visual cues - Control group
N/A

Detailed Description

All patients consecutively referred to the Neurorehabilitation Unit of HABILITA between 1st November 2019 and 31th December 2021 were screened. Patient were admitted for outpatients rehabilitation. All particpants could walk independently without walking device. All patients were taking oral administration of levodopa, dopamine agonists, or both, and were evaluated in ON phase.

All the patients gave their written informed consent to take part in the study. The study was approved by the Local Ethics Committee of Bergamo (Reg. Sper. n. 178/19, 11/10/2019) and was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans.

Study Design

Study Type:
Interventional
Actual Enrollment :
52 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized Controlled TrialRandomized Controlled Trial
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Wearable Visual Cueing System for Gait Rehabilitation in Parkinson's Disease: a Randomized Controlled Trial.
Actual Study Start Date :
Nov 1, 2019
Actual Primary Completion Date :
Dec 31, 2021
Actual Study Completion Date :
Dec 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: QWalk Study Group

10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the new wearable cueing system (QWalk)

Device: QWalk Study Group
10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the new wearable cueing system (QWalk)
Other Names:
  • QWalk
  • Active Comparator: Control Group

    10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of traditional visual cues consisting of stripes on the floor

    Other: Traditional visual cues - Control group
    10 individual sessions (5 sessions/week for 2 consecutive weeks). Each session consisted of 60 minutes of conventional physiotherapy plus an additional session of gait training (30 minutes), performed by means of the traditional cues (stripes on the floor)
    Other Names:
  • Traditional cues
  • Outcome Measures

    Primary Outcome Measures

    1. mean gait speed (m/s) change [Change from baseline (Time 0) at the end of the intervention (2 weeks - Time 1) and at the followup (3 months - Time 2)]

      Distance covered by the body in the unit of time

    2. step length (m) change [Change from baseline (Time 0) at the end of the intervention (2 weeks - Time 1) and at the followup (3 months - Time 2)]

      Distance measured from the heel print of one foot to the heel print of the other foot

    3. cadence (step/min) change [Change from baseline (Time 0) at the end of the intervention (2 weeks - Time 1) and at the followup (3 months - Time 2)]

      time of steps per unit time

    4. stance phase duration (%) change [Change from baseline (Time 0) at the end of the intervention (2 weeks - Time 1) and at the followup (3 months - Time 2)]

      time interval between two consecutive foot strikes of the same lower limb expressed as a percentage of the stride duration

    5. double support phase duration (%) change [Change from baseline (Time 0) at the end of the intervention (2 weeks - Time 1) and at the followup (3 months - Time 2)]

      Time of the sub-phase between heel contact of the phase to contralateral foot-off

    Secondary Outcome Measures

    1. CoP sway length (statokinesigram) (mm) change [Change from baseline (Time 0) at the end of the intervention (2 weeks - Time 1) and at the followup (3 months - Time 2)]

      The projection onto a 2-dimensional space of the trajectory of the centre of pressure (COP) of a person during erect stance

    2. mean CoP position along the anteroposterior direction (Eyes Open) change [Change from baseline (Time 0) at the end of the intervention (2 weeks - Time 1) and at the followup (3 months - Time 2)]

      the centroid of all the external forces acting on the plantar surface of the foot

    3. mean CoP position along the mediolateral direction (Eyes Open) change [Change from baseline (Time 0) at the end of the intervention (2 weeks - Time 1) and at the followup (3 months - Time 2)]

      the centroid of all the external forces acting on the plantar surface of the foot

    4. mean CoP position along the anteroposterior direction (Eyes Closed) change [Change from baseline (Time 0) at the end of the intervention (2 weeks - Time 1) and at the followup (3 months - Time 2)]

      the centroid of all the external forces acting on the plantar surface of the foot

    5. mean CoP position along the mediolateral direction (Eyes Closed) change [Change from baseline (Time 0) at the end of the intervention (2 weeks - Time 1) and at the followup (3 months - Time 2)]

      the centroid of all the external forces acting on the plantar surface of the foot

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • diagnosis of idiopathic PD (defined by the UK Brain Bank Criteria);

    • absence of cognitive impairment (Mini-Mental State Examination score ≥ 24);

    • Hoehn & Yahr stage II-IV; mild to severe gait disturbance with score ≥2 at the Unified Parkinson's Disease Rating Scale (UPDRS) motor section III;

    • stable drug usage since at least 3 weeks.

    Exclusion Criteria:
    • past history or current presence of neurological conditions other than PD;

    • orthopedic or visual disturbances severely impairing walking ability;

    • previous deep brain stimulation or other neurosurgery;

    • participation in a rehabilitation program within 2 months before the trial and previous use of cues for gait rehabilitation.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Habilita Zingonia Ciserano Bergamo Italy 24040

    Sponsors and Collaborators

    • Habilita, Ospedale di Sarnico

    Investigators

    • Principal Investigator: Michelangelo Bartolo, Md, PhD, Habilita Zingonia

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Michelangelo Bartolo, Director Neurorehabilitation Unit, Habilita S.p.A.
    ClinicalTrials.gov Identifier:
    NCT05478187
    Other Study ID Numbers:
    • QWalkTrial
    First Posted:
    Jul 28, 2022
    Last Update Posted:
    Jul 28, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Michelangelo Bartolo, Director Neurorehabilitation Unit, Habilita S.p.A.
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 28, 2022